BioVision

07/14

RELATED PRODUCTS:

Alendronate sodium (Cat. No. 2168-50, 250) Pamidronate sodium (Cat. No. 1884-50, 250)


CATALOG #	
AMOUNT:	

STRUCTURE:

Product:

ALTERNATE NAME:

10



2653-10, 50

42446; CGP42446A; ZOL 446

Zoledronic acid hydrate

(1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl)diphosphonic acid; NDC-zoledronate; zoledronate; Zometa; Reclast; CGP

- MOLECULAR FORMULA: C₅H₁₂N₂O₈P₂
- MOLECULAR WEIGHT: 290.10
- **CAS NUMBER:** 165800-06-6
- APPEARANCE: Crystalline solid
- SOLUBILITY: PBS (~ 1.6 mg/ml)
- **PURITY:** ≥98%
- **STORAGE:** Store at -20 °C. Protect from air and moisture
- DESCRIPTION: Zoledronic acid is a third-generation bisphosphonate that inhibits the prenvlation of GTPases critical to the signaling events related to osteoclast-mediated bone resorption. It displays high affinity for hydroxyapatite ($K_i = 3.47 \mu M$) and binds directly to mineralized bone where it decreases bone resorption by inhibiting osteoclast proliferation and inducing osteoclast apoptosis. At micromolar concentrations, zoledronic acid demonstrates antitumor effects in vitro against breast, prostate, and myeloma cancer cells by inducing cytostasis and prevents bone metastases through its inhibitory effects on adhesion molecules, tumor cell invasion, and angiogenesis. Zoledronic acid has been used in the treatment of osteoporosis, Paget's disease, metastatic bone disease, multiple myeloma, hypercalcemia of malignancy, and skeletal-related events associated with metastatic castrateresistant prostate cancer.

HANDLING:

Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

FOR RESEARCH USE ONLY! Not to be used on humans.